Abstract
Phospholipids (PLs) are amphiphilic molecules that were essential for life to become cellular. PLs have not only a key role in compartmentation as they are the main components of membrane, but they are also involved in cell signaling, cell metabolism, and even cell pathophysiology. Considered for a long time to simply be structural elements of membranes, phospholipids are increasingly being viewed as sensors of their environment and regulators of many metabolic processes. After presenting their main characteristics, we expose the increasing methods of PL detection and identification that help to understand their key role in life processes. Interest and importance of PL homeostasis is growing as pathogenic variants in genes involved in PL biosynthesis and/or remodeling are linked to human diseases. We here review diseases that involve deregulation of PL homeostasis and present a predominantly muscular phenotype.
Keywords: phospholipids, mass spectrometry, muscle, disease, membrane, endoplasmic reticulum, mitochondria
1. Introduction
Life is amazing. The organization of ‘only’ four major types of biological macromolecules constitutes the majority of the dry weight of the human body. Specifically, carbohydrates, proteins, nucleic acids, and lipids perform an incredible variety of functions in the organism. Lipids, also previously known as ‘lipin’ and ‘lipoid’, are a huge family without a real consensual definition from a chemical or biological point of view. In 1920, Bloor from the department of Biochemistry and Pharmacology of The University of California, proposed a classification of lipids in three groups, simple lipids with fats, oils and waxes; compound lipids including phospholipids (PLs) and glycolipids; and a last group including derived lipids (fatty acids (FA), steroids, etc.) [1]. Of all the different lipids, PLs were indispensable to the appearance of life since they can delimit cellular compartments [2,3]. After presentation of the basic concepts on PLs, we present how to isolate, separate, and identify these molecules. The importance of PLs in numerous biological functions is highlighted by rare genetic diseases that involved deregulation of PLs homeostasis. We will center this review on diseases with a predominantly muscular phenotype.
2. Basic Concepts on PLs
Phospholipids include phosphatidic acid (PA), phosphatidylglycerol (PG), phosphatiylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), cardiolipin (CL), and sphingomyelin (SM). Among the PLs, the most abundant are glycerophospholipids (or phosphoglycerides), whose common structure comprises a polar head containing a glycerol to which is attached a phosphate group carrying an additional molecule (which gives its identity to the lipid) and two fatty acids (hydrophobic hydrocarbon chains, sn1 and sn2) [4] (cf. Figure 1). The polar head group can be simply a hydrogene in the case of phosphatidic acid; be an ethanolamine, choline, serine, inositol, or glycerol group; and even a phosphatidylglycerol for cardiolipin. Another abundant type of PL is represented by sphingomyelins, which are phosphosphingolipids (a sub-class of sphingolipids). SM contains a sphingosine (a fatty alcohol containing 18 carbons) bound to phosphocholine and a fatty acid. PLs are specialized lipids, which have multiple names depending on biologist or chemist point of view despite a well-defined but diverse and complex structure. Several classifications of lipids exist according to, for example, their chemical structure or biological origin, but without any real consensus [4]. For example, the fatty acid names depend on the carbon length and the presence of double bonds, but the numbering can be different from the biological or the chemical point of view (cf. Figure 2 and Table 1). Nevertheless, the International Union of Pure and Applied Chemistry (IUPAC) has brought about progress into establishing a chemical nomenclature and terminology for specific scientific fields (https://iupac.org/, accessed on 3 May 2021). Moreover, the database LIPID MAPS (Metabolites and Pathways Strategy—https://www.lipidsmaps.org/, accessed on 3 May 2021) constitutes an important tool for lipidomic analysis, with structures and annotations of bulk lipids [5,6,7]. Importantly, most organic molecules are largely mobile depending on their physical and chemical environment (cf. Figure 2).
Figure 1.
The great diversity of phospholipids.
Figure 2.
FA nomenclature. The chemical structure of FA showing the physiological numbering (black), the first double bond being at the third or sixth carbon from the omega start, and the chemical numbering (red) with conventions for the double bond location (E in cis, Z in trans). One of numerous possibilities of 3D representation was obtained thanks to Molview [11]. 3D structure is influenced by local environments such as pH.
Table 1.
The importance of the double bond position.
Fatty Acid | 18:1 | 18:2 | 18:3 | ||||||
---|---|---|---|---|---|---|---|---|---|
Mass and
Formula |
282.26 and C18H34O2 | 280.24 and C18H32O2 | 278.22 and C18H30O2 | ||||||
Systemic Name | Octadecenoic acid | Octadecadienoic acid | Octadecatrienoic acid | ||||||
Number of
Lipid Records |
43 | 101 | 63 | ||||||
Common Name |
Double Bond
Position |
Number of
PubMed References |
Common Name |
Double Bond
Position |
Number of PubMed
References |
Common Name |
Double Bond
Position |
Number of
PubMed References |
|
Example | Oleic acid | 9Z | 23,694 | Linoleic acid | 9Z, 12Z | 24,310 | α-Linolenic acid | 9Z, 12Z, 15Z | 7036 |
Trans- vaccenic acid |
11E | 325 | Rumenic acid | 9Z, 11E | 316 | γ-Linolenic acid | 6Z, 9Z, 12Z | 3145 | |
Cis-vaccenic acid | 11Z | 202 | Linoelaidic acid | 9E, 12E | 25 | Punicic acid | 9Z, 11E, 13Z | 111 | |
Petroselinic acid | 6Z | 67 | Sebaleic acid | 5Z, 8Z | 9 | Pinolenic acid | 5Z, 9Z, 12Z | 56 | |
Petroselaidic acid | 6E | 4 | Vaccelenic acid | 11E, 15Z | 2 | Jacaric acid | 8Z, 10E, 12Z | 13 |
Formula of the fatty acid can be deduced from its systematic name. Records lipid from https://lipidmaps.org/data/chemdb_lm_text_ontology.php?ABBREV=FA%2018:3 (accessed on 3 May 2021) and records from PubMed https://pubmed.ncbi.nlm.nih.gov/ (accessed on 3 May 2021). (E: trans double bond, Z: cis double bond).
The molecular diversity of phospholipids is very large and depends not only on the polar head, the carbon length (short/medium/long/very long), and the number of carbon chains (from one in lyso-PL to four in cardiolipin), but also on the degree of double bonds (responsible for molecular rigidity) and their position (cf. Figure 2). There are also plasmalogens, PL analogs containing an ether or vinyl ether group instead of the usual ester function [8]. The position of a fatty acyl chain in sn1 or sn2 increases the diversity further. Thus, the beautiful and large family of phospholipids already contains more than 40,000 natural molecules [2,9]. Precise and structural identification of lipids in a biological medium has been underway for more than 30 years and is becoming possible thanks to the development of mass spectrometry [10]. Of note, the use of common name of fatty acid should be carefully used unless the position of the double bond and the cis and trans isomeres are fully identified. We advise using the systematic name if no information on double bond position is provided (cf. Table 1).
In order to present the different PLs in more detail, we chose to follow the order of lipid retention following liquid chromatography using a polar stationary phase (polyvinyl alcohol grafted silica column). This allows phospholipids to be separated by polarity, followed by a charged aerosol detector Corona CAD and a high-resolution mass spectrometer [12] (cf. Figure 3 and Table 2). Phosphatidic acid is the simplest PL, one of the least abundant PL present in the plasma membrane, but is central in PL biosynthesis [13]. PA has been involved mainly in membrane biophysical properties and in various signaling pathways such as adipogenesis or autophagy [14]. Three major pathways can generate PA: (i) From the acylation of lyso-PA (LPA) by lysophosphatidic acid acyltransferases (LPAAT) (cf. Figure 4). LPA can be obtained from glycerol-3-phosphate (G3P) thanks to the enzymatic action of glycerol-3-phosphate acyltransferase (GPAT). (ii) From the hydrolysis of phosphatidylcholine by the phospholipase D. (iii) From the phosphorylation of diacylglycerol (DAG) by a diacylglycerol kinase (DGK 10 isoforms in human) [13,15]. Importantly, PA is a major precursor of PL biosynthesis. DAG and CDP-DAG (cytidine diphosphate-DAG) are key intermediates that can be obtained from PA thanks to phosphatidic acid phosphatases (PAP or diacylglycerol-3-phosphate phosphohydrolase as systematic name) and CDP-DAG synthetase (CDS or CTP:phosphatidate cytidylyltransferase as systematic name), respectively [14]. They are two types of PAP, type I encoded by lipin genes and type II mainly found in the plasma membrane known as lipid phosphate phosphatases.
Figure 3.
TIC (total ion chromatogram) by MS ESI-neg profiling and Corona CAD analysis for phospholipid class detection. Standard analysis of 0.3 g/L of PA, PG, CL, PI, PE, PS, LPE, PC, SM, and LPC.
Table 2.
Main characteristics of phospholipids.
Phospholipid Group | % of Total Lipids in Eukaryotic Cells [27] |
Main Biosynthesis Site |
Main Characteristics |
---|---|---|---|
Phosphatidic acid PA |
1–2 | ER | The simplest PL Main precursor for PL synthesis Inverse cone |
Phosphatidylglycerol PG |
<1 | Mitochondria | Precursor of cardiolipin |
Cardiolipin CL |
2–5 | Mitochondria | Present only in mitochondrial membranes Contains four fatty acyl chains Inverse cone |
Phosphatidylinositol PI |
10–15 | ER | Source of inositol 1,4,5 triphosphate (IP3) Cylinder shape |
Phosphatidylethanolamine PE |
15–25 | ER and also mitochondria from PS |
Second most abundant PL Inverse cone |
Phosphatidylserine PS |
5–10 | ER | Mostly present in the inner leaflet of the cell membrane, when externalized they became a signal of recognition for cell phagocytosis by macrophages (characteristic of apoptosis) Cylinder shape |
Lysophosphatidylethanolamine LPE |
ND | Obtained from phospholipase action |
Contains one fatty acyl chain Hydrolysis of one fatty acid of a PE by a phospholipase |
Phosphatidylcholine PC |
45–55 | ER | The most abundant (outer leaflet of cell membrane) Constitutes a reserve of choline and methyl groups Formerly called lecithin Cylinder shape |
Sphingomyelin SM |
5–10 | Golgi | Phosphocholine bound to ceramide Abundant on the outer leaflet of the membrane Cylinder shape |
Lysophosphatidylcholine LPC |
ND | Obtained from phospholipase action |
Contains one fatty acyl chain Hydrolysis of one fatty acid of a PC by a phospholipase |
Figure 4.
Diacylglycerol (DAG) and CDP-DAG are two key elements in PL biosynthesis. GPAT: glycerol-3-phosphate acyltransferase, LPAAT: lysophosphatidic acid acyltransferases, PAP: phosphatidic acid phosphatases, DGK: diacylglycerol kinase, CDS: CDP-DAG synthetase, DAGAT: diacylglycerol acyl transferase, ALCAT1: AcylCoA:lysoCL acyltransferase 1, MLCAT1: monolysoCL acyltransferase 1, TAZ: tafazzin, EK: ethanolamine kinase, ET: CTP:phosphoethanolamine PE cytidylyltransferase, EPT: ethanolaminephosphotransferase, PSD: phosphatidylserine decarboxylase, PSS2: phosphatidylserine synthase 2, CK: choline kinase, CT: CTP: phosphocholine cytidylyltransferase, CPT: cholinephosphotransferase, PSS1: phosphatidylserine synthase 1, SMS: sphingomyelin synthase.
From the liponucleotide CDP-DAG, phosphatidylglycerol and 1,3-bis(sn-3′-phosphatidyl)-sn-glycerol known as cardiolipin and phosphatidylinositol can be synthetized [16]. PG has low abundance, less than 1% of total PLs in mammal cells, and is relatively saturated compared to other PLs [17]. Cardiolipins are unique among the PL family as they are specifically present in mitochondria membranes, especially in inner membrane, and composed of a dimeric phosphatidic acid containing two phosphates and four acyl chains [18] with molecular structure similarity with PG [16,19]. This distinctive four acyl chain composition induces a cone-shaped PL that has specific properties such negative membrane curvature and proton buffering [20]. Moreover, this specific structure leads to an important variety of CL species due to a huge diversity of acyl composition. From the biosynthesized ‘nascent’ CL, there is further remodeling leading to hetero-acylated or homo-acylated CL [16]. Three different enzymes are involved in acyl synthetic transformation: tafazzin (a trans-acylase) and two acyl-transferases MLCAT1 (monolysoCL acyltransferase 1) and ALCAT1 (acylCoA:lysoCL acyltransferase 1) [16]. This lipid dimer with four acyl chains was initially isolated from heart beef as cardiomyocytes are the richest cells in terms of mitochondria [21]. In heart and skeletal muscle, the main cardiolipin specie is composed of four C18:2 acyl chains. The last PL synthesized from CDP-DAG is PI, and the biosynthesis takes place in the ER thanks to PIS (phosphatidylinositol synthase), whereas PG and CL biosynthesis are orchestrated in mitochondria [18]. Despite a relatively minor representation in membrane composition (around 10%), PI is an important PL due to the generation of several phosphorylated derivatives at the inositol ring, which are involved in a plethora of cell signalizations such as membrane trafficking and regulation of protein function [18]. Strikingly, the fatty acyl composition of PI is mainly C18:0/C20:4 in numerous rodent tissues, and the consequences of this specific fatty acyl composition are not well understood [22].
PC and PE, the two most abundant phospholipids, are generated by the Kennedy pathway by which DAG is transferred to CDP-choline and CDP-ethanolamine, respectively (cf. Figure 4). These intermediates are obtained from phospho-choline and phospho-ethanolamine thanks to CTP:phosphocholine cytidylyltransferase (CT) and CTP:phosphoethanolamine PE cytidylyltransferase (ET) [23]. PE can generate PC by methylation reactions by phosphatidylethanolamine N-methyltransferase (PEMT). PE can also be produced specifically in the mitochondria by a phosphatidylserine decarboxylase (PSD) from PS. Two enzyme phosphatidylserine synthase 1 and 2 responsible for base-exchange reactions synthesize PS from PC and PE, respectively [24]. PC are also involved in sphingomyelins (which do not have glycerol in their structure) synthesis in the Golgi from ceramides (produced in the ER) by sphingomyelin synthase (SMS), which transfers phosphocholine from a PC [25].
Details in PL biosynthesis pathways are reviewed in [19,26,27]. Multiple pathways can lead to PL synthesis, re-synthesis, or remodeling using various intermediates, and these pathways could happen in different membranes such as plasma membrane, ER membrane, lysosome/peroxisome membrane, or mitochondria membranes. De-acylation and re-acylation reactions due to a large number of phospholipase enzymes add further difficulties in pinpoint the precise PL composition [28]. Each cell has a unique PL fingerprint, making it difficult to unravel the physiological and pathophysiological significance [18]. The development of methods that track PL movement from their place of synthesis to their final organelle destination will help to decipher their role in cells.
3. Main Methods for PL Analysis
In 2021, more than 200,000 results were obtained through a PubMed search using the keyword “phospholipids”. Evolution of the number of publications is closely linked to technological progress in the lipid research field, particularly with chromatography techniques (first thin layer, then gas and liquid phase) associated with ever more efficient detectors. Since the early 2000s, metabolomic screening approaches using coupled mass spectrometry have been flourishing.
Liquid–liquid extraction (LLE) is the most widely used method for extracting lipids from a biological medium. The first LLE method was developed by Folch in 1957 using a mixture of chloroform, methanol, and water (8:4:3 v/v/v) [29]. Most of the lipids (from a wide range of polarity) are recovered from the sample [30]. However, PL extraction yield can vary from 50 to 90%, some of them remaining in the aqueous phase [31]. The Folch method was subsequently modified by Bligh and Dyer to increase the proportion of polar lipids extracted by using a 1:2:0.8 v/v/v mixture of chloroform, methanol, and water [32]. Since then, many protocols have been developed to optimize extraction efficiency according to the lipids of interest or the nature of biological samples studied and to limit the use of toxic solvents such as chloroform [33].
The characterization of PL molecular species is mainly performed with mass spectrometry (MS) tools generally coupled with chromatographic techniques. Various separation methods have been developed, depending on the lipid mixture and the questions to answer [34,35]. Gas chromatography (GC), often used for fatty acid analysis, is not suitable for whole PL analysis as PLs are too polar and not very volatile. The overall FA composition can be obtained by GC/MS after hydrolysis of PLs, but this method does not allow for identification of plasmalogens ether or vinyl ether acyl chain. Liquid chromatography (LC) is much more suitable for PL analysis including plasmalogens. Normal phase HPLC (high-performance LC) has the advantage of separating PLs according to the polar head nature (allowing quantification of PL classes on a reduced retention time). This facilitates the structural identification of molecular species; however, it requires the use of hazardous solvents [36]. Reverse phase HPLC separates PL molecular species on the basis of hydrophobicity of FA chains, depending on carbon length and number of unsaturations; this induces mixing of lipid classes and difficulties for the structural characterization of species [37]. A more environmentally friendly approach is the super critical fluid chromatography (SFC), which has the advantages of normal phase HPLC while using eco-compatible (CO2 in super critical phase, H2O) and less toxic solvents (acetonitrile) [38].
Once they are separated by chromatography, mass spectrometry is the most efficient tool for characterizing PLs, which ionize very well in electrospray. The analysis can be done in a non-targeted (profiling) or targeted (semi-quantitative) way [39]. In lipidomic profiling, high-resolution mass spectrometry allows to obtain the atomic composition of the whole molecule (generally in adduct form). If chromatography does not provide information on PL classes, fragmentation spectra are essential to identify the molecular structure precisely. Positive mode fragmentation confirms the nature of the polar head, while negative mode fragmentation gives access to FA composition [40]. Although MS is a powerful tool for structural characterization, it provides limited information on positioning of unsaturation on FA chains [38]. Specific methods have been developed with this aim, using alkaline adducts or ozone as reactant gas combined with targeted fragmentation. However, implementation of theses analyses and spectra interpretation are still highly challenging [35]. In the same way, assignment of sn-positions of PL acyl chains is only possible through validated assays based on monitoring the ratio between fragment ions of positional isomers.
Mass spectrometry coupled with chromatographic techniques are lengthy forms of analysis (several dozen minutes) and consume important volumes of solvents. MS can also be used alone, without prior separation, in shotgun MS analysis [41]. This technique is fast and simple to implement, giving access to a global phospholipidomic profile. Very high spectral resolution is required to identify molecular species with similar masses, and separation of isomers is not possible with shotgun analysis. Simultaneous ionization of hundreds of molecules, with different concentrations and polarities leads to ionization suppression, limiting the visibility of low-concentration and/or poorly ionizable species [42].
Quantification of lipid species remains challenging as molecular standards of each species are not available [38]. FA composition will strongly influence ionization, making analogy with different molecular species not possible [43]. In general, the quantification of PLs by species is semi-quantitative.
Phospholipidomics provides large amount of valuable information that implies statistical analysis like other ‘omics’ approaches. Large-scale profiling gives access to the phospholipidome of cells, tissues, or various samples at a specific time. This PL fingerprint is an important step towards understanding PL metabolism and disturbances.
4. Phospholipids in Biological Membranes
The fluid-mosaic membrane model was proposed from the 1970s by Singer and Nicolson and revisited in 2014 by Nicolson [44,45]. Membranes, interacting with the cytoskeletal network and extracellular matrix, are dynamic structures composed not only of lipids, but also of membrane proteins. Dynamic and reversible micro and even nano-size structures, such as lipid rafts, can be present in the biological membranes [45,46,47]. Membranes are integrated elements within cells, tissues, and organisms; they are sensitive and can react to variation of their environment [45]. We will focus on PLs, the main lipid present in the asymmetrical cell membranes [46]. Their inner leaflet is composed of PS, PA, and PI, which induce a strong negative charge compared to the relatively uncharged outer membrane with a majority of PC and SM [48]. As mentioned previously, the main site of phospholipid biosynthesis is the endoplasmic reticulum membrane, followed by mitochondrial membranes; these are two key organelles for cellular homeostasis, controlling among other things calcium content and ATP production [27]. Vance’s research has shown in the beginning of the 1990s that ‘membrane bridges’ between the ER and mitochondria were able to synthesize a large variety of phospholipids [49,50]. These two organelles are in some places very close (around 10 nm apart), and these connecting zones have been named mitochondria-associated membranes (MAM) or mitochondria–ER connect (MERC) [51,52,53,54]. The MAMs allow for the existence of calcium microdomains [55] and energy microdomains [56], which require proximity between mitochondria and ER, but also exchange of PL, although the transporters associated with certain PL have not been clearly identified [52,54]. The distribution of PL species varies among the different organelles [27,57] and can evolve with changes in the cellular environment and with events such as aging, diet, or the circadian clock [58,59,60].
Membranes are dynamic structures. This is especially well known for mitochondria as they can form a filamentous or a fragmented network [59,61,62]. The inner leaflet of mitochondria is very peculiar since it includes only three major PLs: nearly 40% PC, 40% PE, and more than 15% cardiolipin. This composition, rich in PE of conical shape and CL (four fatty acid chains), allows for the formation of numerous invaginations of the inner membrane, the mitochondrial cristae. Regarding the ER, more than half of its PLs are PCs. The ER is composed of domains that perform multiple functions, leading to a heterogeneous protein distribution. A distinction is made between the smooth ribosome-free ER and the rough ribosome-containing ER, which is involved in protein biosynthesis. Muscle cells possess not only the classic ER but also a vast network of specialized membranes associated with myofibrils called the sarcoplasmic reticulum (SR) [51]. The SR allows the intake, storage, and flow of calcium required for muscle contraction. Avoiding calcium leakage from the ER/SR and uncoupling of mitochondria is essential for optimal cellular function. The integrity of the membranes of these organelles is crucial for this, and phospholipids should play an important role [63].
Another important parameter in membrane composition is cholesterol, particularly for plasma membranes [46]. As the molecular ratio is roughly 0.8 cholesterol per phospholipid in plasma membranes [48], their interaction is surely a key parameter for cell homeostasis, cell signaling, and pathophysiology. Two of the key partners for cholesterol are PC and sphingomyelins [45], which are mainly present in the plasma membrane and lysosomes.
The PL composition of the membranes of the numerous organelles and the plasma membrane is adapted to each cell type to meet different physiological needs [64,65]. Depending on the type of carbon chains of each PL, the membranes will be more or less fluid, flexible, compact, and thick, giving them particular properties [64]. The PLs with saturated fatty acids make the membranes rigid, whereas the membranes that contain fatty acids with several unsaturations will be more fluid [66]. The state (fluid vs. rigid) of the membrane can modify cellular processes such as membrane traffic, vesicle fusion, or formation of lipo-protein complexes at the membrane [64].
5. Importance of PLs in Striated Muscle Functions
The local coupling of the sarco-endoplasmic reticulum and mitochondria, which controls muscle contraction and energy production, appears central to skeletal and cardiac muscle function and dysfunction. Integrity of the membrane organelles is crucial to limit calcium leak from the ER/SR and mitochondrial proton and electron escape. Furthermore, skeletal muscles are subjected to an aperiodic and highly variable mechanical force that is transmitted to membranes [67]. Thus, it is important to study more in detail the membrane composition, particularly the amphiphilic molecules that participate in optimal muscle function. Many questions remain partially unresolved; for example, how are they essential to the dialogue between ER and mitochondria? What links exist between phospholipids and skeletal or cardiac muscle diseases? Is PLs dyshomeostasis a cause or a consequence of muscle dysfunction?
Indeed, PL imbalances can disrupt cell and organelle homeostasis and participate in various pathologies [68]. The indisputable evidence of these points comes from rare genetic diseases. In the Orphanet classification, a group of disorders of PLs, sphingolipids, and fatty acids biosynthesis (ORPHA:352301) was created in 2013 [69,70] and is divided in three sub-groups depending on the predominant phenotypical involvement, namely, (i) central nervous system (ORPHA:352306), (ii) peripheral nerves (ORPHA:352309), and (iii) skeletal muscle (ORPHA:352312). The latter highlights a key role of PLs in muscle physiology with five genetic diseases in which the primary defect directly targets PL: Barth syndrome (ORPHA:111, associated with defects of the TAZ gene encoding tafazzin), congenital cataract-hypertrophic cardiomyopathy-mitochondrial myopathy syndrome also known as Sengers syndrome (ORPHA:1369, due to defects of AGK acylglycerol kinase, SLC25A4 solute carrier family 25 member 4), genetic recurrent myoglobinuria (ORPHA:99845, associated with the Lipin1 gene LPIN1, MTCO1, or MTCO2 mitochondria DNA-encoded cytochrome C oxidase), megaconial congenital muscular dystrophy (ORPHA:280671—CHKB, choline kinase beta), and neutral lipid storage disease (ORPHA:165—ABHD5, abhydrolase domain containing 5, PNPLA2/ATGL patatin-like phospholipase domain-containing 2) (cf. Table 3).
Table 3.
PL alterations involved in muscular diseases.
Gene Mutated |
Protein and Function | Disease | Muscular Symptoms |
Lipid Disorders | Animal Experimental Models | Ref. | |
---|---|---|---|---|---|---|---|
ORPHA 352312: group of disorders of PL, sphingolipids and
FA biosynthesis with skeletal muscle characteristics |
TAZ chromosome X |
Tafazzin Phospholipid-lysophospholipid transacylase Catalyzes remodeling of immature CL to its mature composition |
Barth syndrome | Dilated cardiomyopathy Skeletal muscle weakness |
Reduced level of CL Increased level of mono-lysocardiolipin |
|
[71,72,73] |
AGK chromosome 7 |
AGK Acylglycerol kinase Phosphorylates MAG and DAG to form LPA and PA |
Sengers syndrome | Hypertrophic cardiomyopathy Skeletal myopathy Congenital cataract |
Defects in mitochondria and storage of lipids in muscle (skeletal and heart) |
|
[74,75,76,77] | |
LPIN 1 chromosome 2 |
Lipin-1 Phosphatidate phosphatase Catalyzes the conversion of PA to DAG |
Myoglobinuria | Rhabdomyolysis Muscle fiber loss |
Hyper-triglyceridemia Accumulation of PL intermediates |
|
[78,79,80,81] | |
PNPLA2 chromosome 11 |
ATGL Adipose triglyceride lipase Catalyses the hydrolysis of TAG into DAG |
Slowly progressive myopathy: neutral lipid storage disease with myopathy (NLSDM) Arrhythmogenic cardiomyopathy |
Distal muscle weakness Cardiomyopathy |
Accumulation of lipid droplets(TAG) in multiple tissues Altered energy metabolism Lipidosis of internal organs |
|
[82,83,84,85] | |
CHKB chromosome 22 |
CHKB Choline kinase β Catalyzes the first step in PE biosynthesis |
Megaconial congenital muscular dystrophy | Mitochondrial structural (enlargement) and functional abnormalities | Decreased level of PC |
|
[86,87,88,89] | |
Disease not listed in ORPHA 352312 despite gene mutation in gene involved in PL biosynthesis, sphingolipids, and FA synthesis |
HACD1 chromosome 10 |
HACD1 3-Hydroxyacyl-CoA dehydratase 1 Catalyzes the third of the four reactions of the long-chain FA elongation cycle |
Congenital fiber-type disproportion, rare internalized nuclei | Congenital myopathy with proximal ± distal muscle weakness, progressively improving over time | Increased concentrations of ≥ C18 and mono-unsaturated FA |
|
[90,91,92] |
ACADVL chromosome 17 |
VLCAD Very long chain Acyl-coA dehydrogenase Involved in the β-oxidation pathway (FA longer than C16) |
VLCADD (VLCAD deficiency) | Cardiomyopathy Myopathy with intermittent myalgia and rhabdomyolysis, progressive muscle weakness, often dropped head |
Defective long-chain FA oxidation |
|
[93,94,95,96,97] | |
ACADM chromosome 1 |
MCAD Medium-chain acyl-coenzyme A dehydrogenase Involved in the β-oxidation pathway (C4 to C12 acyl chain) |
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) | Myopathy exertion induced myalgia, progressive proximal limb weakness Secondary carnitine deficiency |
Accumulation of FA intermediates |
|
[98,99,100] | |
HADHA chromosome 2 |
MTP Mitochondrial trifunctional protein Catalyzes three out of the four steps in beta oxidation |
Mitochondrial trifunctional protein deficiency (MTP deficiency or MTPD) | Skeletal myopathy, episodic rhabdomyolysis, peripheral neuropathy, cardiomyopathy in severe cases | Decreased long-chain FA oxidation |
|
[101,102,103] | |
CGI-58 chromosome 3 |
ABHD5 Alpha/beta hydrolase domain containing 5 Lipid droplet-associated protein that activates ATGL |
Chanarin–Dorfman syndrome (neutral lipid storage disease) |
Moderate myopathy Possible cardiomyopathy | Accumulation of TAG droplets |
|
[104,105,106,107,108] | |
CPT2 chromosome 1 |
CPT2 Carnitine palmitoyltransferase 2 Catalyzes the transfer of FA from cytoplasm to mitochondria |
Carnitine palmitoyl-transferase II deficiency | Episodic myalgia, muscle weakness, and rhabdomyolysis with myoglobinuria | Reduced the rates of long-chain FA oxidation into carbon dioxide |
|
[109,110,111,112] | |
Alteration of PL in inherited form of myopathies due to
mutation in genes without a direct link to PL biosynthesis |
DYSF chromosome 2 |
Dysferlin Involved in the sarcolemma repair mechanism, interacts with caveolin 3 |
Dysferlinopathy, including: limb girdle muscular dystrophy type 2B (LGMD2B) Miyoshi myopathy |
Proximal, distal, or proximo-distal myopathy, predominantly involving lower limbs Rhabdomyolysis |
Early intra-myocellular lipid accumulation (sphingolipids, PLs, cholesterol) |
|
[113,114,115,116] |
DMD chromosome X |
Dystrophin Involved in the connection of the cytoskeleton of a muscle fiber to the extracellular matrix through the cell membrane |
Duchenne muscular dystrophy Becker muscular dystrophy |
Cardiomyopathy with myocardial fibrosis, muscle weakness and muscle fiber necrosis, respiratory failure |
PL dyshomeostasis Increased PC and SM |
|
[117,118,119,120,121,122,123] | |
CAV3 chromosome 3 |
Caveolin3 Component of caveolae plasma membrane (possible scaffolding role for caveolin-interacting molecules) |
Rippling muscle disease LGMD Isolated familial hypertrophic cardiomyopathy HyperCKemia and myalgia |
Skeletal muscle weakness Muscle hyperirritability triggered by stretch |
Decreased CL |
|
[124,125,126,127] |
Pathogenic variants in the TAZ gene, encoding a transacylase necessary for cardiolipin remodeling, are responsible for Barth’s syndrome (BTHS), a devastating disease affecting the neuromuscular and metabolic systems, characterized by dilated cardiomyopathy and skeletal myopathy in infants [128]. Despite normal content of PE and PC, decreased levels of long polyunsaturated chains (20:4 and 22:6) and increased of 18:2 (probably linoleic acid) has been described in children with this syndrome [129]. Mitochondria in BTHS have important alterations of the cristae ultrastructure (fold and invagination of the inner mitochondrial membrane) leading to defective ATP production [130,131]. Studies involving patients with Barth syndrome are extremely valuable to highlight the key roles played by CLs in mitochondrial respiratory function. Thus, the alteration of CL maturation in these patients has been shown to lead to an instability of respiratory chain supercomplexes that affects complex I activity, thereby demonstrating the importance of CLs for complex I-containing supercomplex formation and function [132].
Sengers syndrome, due to pathogenic variants in the AGK gene, shares strong similarities with Barth syndrome, including skeletal myopathy and cardiomyopathy (hypertrophic), being lethal within the first year of life in around half of the patients [133]. The AGK kinase is involved in phosphorylation of MAG (monoacylglycerol) to LPA and DAG to PA, which are largely involved in PL biosynthesis. The depletion by siRNA of AGK in PC-3 prostate cancer cells induce a reduction of LPA and PA in mitochondria [134], whereas in HEK293 (human embryonic kidney), no changes were observed [135]. To the best of our knowledge, no phospholipidomic data are available in muscle cells. Moreover, the protein belongs to the translocase of the inner mitochondrial membrane TIM22 complex [136]. This multi-protein complex is involved in the import and assembly of mitochondrial carrier proteins such as ANT (adenine nucleotide translocator) [136].
Pathogenic variants in the CHKB gene, encoding choline kinase beta, an enzyme involved in the synthesis of phosphatidylcholine, cause megaconial congenital muscular dystrophy in humans (associated with developmental delay and autistic behavior) and to rostrocaudal muscular dystrophy in mouse [86,87,88]. Decreased content of this most abundant phospholipid in the eukaryotic membrane leads to giant mitochondria localized in the periphery of muscle fibers [137]. Mitochondrial membrane potential is decreased in patient-derived cells, and a reduction of mitochondrial respiratory complex I activity is observed in their skeletal muscles [138].
Patients with a genetic defect causing loss of function of LPIN1 (gene coding for LIPIN 1) develop myopathy, affecting both skeletal muscle and the heart [81]. Investigations into the links between lipid balance, more specifically phospholipid balance, and skeletal muscle function have confirmed that modification of certain proteins involved in the biosynthesis of PLs influences PLs levels. Loss of Lpin1 in mice alters PL levels in gastrocnemius muscle, with significant increase in PC, PE, PI, PS, and PG levels, as well as in PA levels. LIPIN 1, a Mg2+-dependent phosphatidate phosphatase, thus appears to be an important enzyme in the homeostasis of phospholipids in muscle [81].
Other genes involved in PL, sphingolipid, and fatty acid biosynthesis leading to a predominantly muscular phenotype when mutated in humans could extend the ORPHA:352312 group (cf. Table 3). For example, pathogenic variants of HACD1 (3-hydroxyacyl-CoA dehydratase 1), an ER resident enzyme involved in the synthesis of very long-chain fatty acids, have been associated with congenital myopathies in humans and in dogs [90,91,139]. In Hacd1-deficient mice, skeletal muscle mitochondria exhibit a significant decrease in CL content in the mitochondrial inner membrane [91]. This is associated with important cristae remodeling and strong alterations of mitochondrial coupling, leading to a higher energy dissipation. An in vitro assay showed that enrichment of mitochondrial membranes with CLs rescued the coupling efficiency of ATP synthase and therefore the mitochondrial electron transfer chain function, highlighting the key role of CLs in the respiratory chain [117,121,122,123].
Alteration of PLs is also present in inherited form of myopathies due to pathogenic variant in genes without a direct link to PL biosynthesis (cf. Table 3). In muscle from DMD (Duchenne muscular dystrophy) patients, increased PC and SM have been reported [119]. In EDL muscle from the mdx mice (the murine model of DMD, devoid of dystrophin), an increase PC containing saturated acyl chain (16:0 and 18:0) and a decrease PE and PC containing long and polyunsaturated acyl chain (22:6) and (20:4) were found. Genetic rescue in mdx mice leading to truncated dystrophin expression was able to restore the PL profiles [121]. Additionally, the increased PC/PE ratio in mdx mice is corrected by the transgenic expression of FAS (fatty acid synthase), stearoyl-CoA desaturase-1 (SCD1), and Lipin1 [140]. In dysferlinopathies, muscle diseases due to pathogenic variants in the gene encoding dysferlin, a transmembrane protein implicated in protein trafficking, lipid droplets accumulate in myofibers [141]. Molecular remodeling of the lipidome has been observed in skeletal muscle of BLAJ mouse (a dysferlinopathy model), with increased content of species of sphingomyelin, PC, LPC, PE, and LPE in quadriceps from BLAJ compared to WT [142].
In skeletal muscle, ER stress and the stress response provided by the UPR (unfolding protein response) system can be activated under different conditions, including inherited myopathies. The UPR system may be triggered by the accumulation of misfolded proteins, altered calcium balance, or the presence of reactive oxygen species (ROS) [143,144]. Since PLs are synthesized in the ER and constitute its membranes, a link can exist between alteration of the phospholipid balance and reticulum damage. Indeed, loss of Lpin1 gene function in mice induced, in addition to altered PL composition, a significant increase of different ER stress markers (Bip, Fgf21, Gdf15, HSP90b1, and Edem1) [81]. This study also showed morphological alteration of the mitochondria associated with ER stress [81], consistent with the fact that the maintenance of the phospholipid balance is also ensured by the exchange of PLs between ER and mitochondria via the MAMs, and that mitochondria are a site for the synthesis of certain PLs such as PG or CL.
Thus, PL alterations in mouse muscles can be associated with changes in other pathways, such as ER stress, mitochondrial dysfunction, and disturbed cell homeostasis. Taken together, these changes are associated with different inherited myopathies. Although all the roles of PLs at the muscle level are not yet clearly defined, these molecules seem to be important to maintain cell homeostasis and organelle integrity, ensuring normal muscle function. Therefore, a so-called ‘normal’ composition of PLs or PL homeostasis, particularly in the ER/RS membranes and mitochondria, key structures in muscle, is important for maintain motor function, contraction, muscle development and regeneration.
6. Conclusions
Phospholipids are a large family of diverse lipids with a wide variety of structures and physico-chemical properties. The role of PLs in the physiology and pathophysiology of skeletal muscles has been underanalyzed, although muscle is one of the largest metabolic organs. More efforts should be made to fully understand the mechanisms of PL dyshomeostasis and their pathophysiological relevance, which may further improve our understanding of muscular diseases. In particular, characterizing the mechanisms by which PLs modulate the endoplasmic reticulum and mitochondria functions could contribute to a better understanding of the pathophysiology of inherited or acquired myopathies. Thanks to the development of new generation of advanced lipid analysis technologies, phospholipidomics can now help elucidate the importance of PLs in muscle function. Comprehensive PL profiling is necessary for the discovery of diagnostic biomarkers and new therapeutic targets, as well as for the development of personalized therapeutic approaches to treat or slow the progression of muscle pathologies.
Acknowledgments
We thank all the Ferreiro’s lab members for their continuous support.
Author Contributions
Writing and editing: R.B., A.S., B.P., M.C., A.F., J.P., and M.M. Conceptualization and supervision: M.M. All authors have read and agreed to the published version of the manuscript.
Funding
This work was funded by the University of Paris and the National Center for Scientific Research.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Bloor W.R. Outline of a classification of the lipids. Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. 1920;17:138–140. doi: 10.3181/00379727-17-75. [DOI] [Google Scholar]
- 2.Zumbuehl A. Artificial Phospholipids and Their Vesicles. Langmuir. 2019;35:10223–10232. doi: 10.1021/acs.langmuir.8b02601. [DOI] [PubMed] [Google Scholar]
- 3.Robertson J.L. The lipid bilayer membrane and its protein constituents. J. Gen. Physiol. 2018;150:1472–1483. doi: 10.1085/jgp.201812153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Christie W.W., Han X. Lipid Analysis—Isolation, Separation, Identification and Lipidomic Analysis. 4th ed. Elsevier; Amsterdam, The Netherlands: 2010. p. 446. [Google Scholar]
- 5.Fahy E., Subramaniam S., Murphy R.C., Nishijima M., Raetz C.R., Shimizu T., Spener F., van Meer G., Wakelam M.J., Dennis E.A. Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 2009;50:S9–S14. doi: 10.1194/jlr.R800095-JLR200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Liebisch G., Fahy E., Aoki J., Dennis E.A., Durand T., Ejsing C.S., Fedorova M., Feussner I., Griffiths W.J., Kofeler H., et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J. Lipid Res. 2020;61:1539–1555. doi: 10.1194/jlr.S120001025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Sud M., Fahy E., Cotter D., Brown A., Dennis E.A., Glass C.K., Merrill A.H., Jr., Murphy R.C., Raetz C.R., Russell D.W., et al. LMSD: LIPID MAPS structure database. Nucleic Acids Res. 2007;35:D527–D532. doi: 10.1093/nar/gkl838. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Dean J.M., Lodhi I.J. Structural and functional roles of ether lipids. Protein Cell. 2018;9:196–206. doi: 10.1007/s13238-017-0423-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kimura T., Jennings W., Epand R.M. Roles of specific lipid species in the cell and their molecular mechanism. Prog. Lipid Res. 2016;62:75–92. doi: 10.1016/j.plipres.2016.02.001. [DOI] [PubMed] [Google Scholar]
- 10.Wenk M.R. Lipidomics: New tools and applications. Cell. 2010;143:888–895. doi: 10.1016/j.cell.2010.11.033. [DOI] [PubMed] [Google Scholar]
- 11.Smith T.J. MolView: A program for analyzing and displaying atomic structures on the Macintosh personal computer. J. Mol. Graph. 1995;13:122–125, 115. doi: 10.1016/0263-7855(94)00019-O. [DOI] [PubMed] [Google Scholar]
- 12.Moulin M., Solgadi A., Veksler V., Garnier A., Ventura-Clapier R., Chaminade P. Sex-specific cardiac cardiolipin remodelling after doxorubicin treatment. Biol. Sex Differ. 2015;6:20. doi: 10.1186/s13293-015-0039-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Zhukovsky M.A., Filograna A., Luini A., Corda D., Valente C. Phosphatidic acid in membrane rearrangements. FEBS Lett. 2019;593:2428–2451. doi: 10.1002/1873-3468.13563. [DOI] [PubMed] [Google Scholar]
- 14.Lutkewitte A.J., Finck B.N. Regulation of Signaling and Metabolism by Lipin-mediated Phosphatidic Acid Phosphohydrolase Activity. Biomolecules. 2020;10:1386. doi: 10.3390/biom10101386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Massart J., Zierath J.R. Role of Diacylglycerol Kinases in Glucose and Energy Homeostasis. Trends Endocrinol. Metab. 2019;30:603–617. doi: 10.1016/j.tem.2019.06.003. [DOI] [PubMed] [Google Scholar]
- 16.Maguire J.J., Tyurina Y.Y., Mohammadyani D., Kapralov A.A., Anthonymuthu T.S., Qu F., Amoscato A.A., Sparvero L.J., Tyurin V.A., Planas-Iglesias J., et al. Known unknowns of cardiolipin signaling: The best is yet to come. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2017;1862:8–24. doi: 10.1016/j.bbalip.2016.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Furse S. Is phosphatidylglycerol essential for terrestrial life? J. Chem. Biol. 2017;10:1–9. doi: 10.1007/s12154-016-0159-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Blunsom N.J., Cockcroft S. Phosphatidylinositol synthesis at the endoplasmic reticulum. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2020;1865:158471. doi: 10.1016/j.bbalip.2019.05.015. [DOI] [PubMed] [Google Scholar]
- 19.Blunsom N.J., Cockcroft S. CDP-Diacylglycerol Synthases (CDS): Gateway to Phosphatidylinositol and Cardiolipin Synthesis. Front. Cell Dev. Biol. 2020;8:63. doi: 10.3389/fcell.2020.00063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Pennington E.R., Funai K., Brown D.A., Shaikh S.R. The role of cardiolipin concentration and acyl chain composition on mitochondrial inner membrane molecular organization and function. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2019;1864:1039–1052. doi: 10.1016/j.bbalip.2019.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Pangborn M.C. Isolation and purification of a serologically acitve phospholipid from beef heart. J. Biol. Chem. 1942;143:247–256. doi: 10.1016/S0021-9258(18)72683-5. [DOI] [Google Scholar]
- 22.Traynor-Kaplan A., Kruse M., Dickson E.J., Dai G., Vivas O., Yu H., Whittington D., Hille B. Fatty-acyl chain profiles of cellular phosphoinositides. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2017;1862:513–522. doi: 10.1016/j.bbalip.2017.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.van der Veen J.N., Kennelly J.P., Wan S., Vance J.E., Vance D.E., Jacobs R.L. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim. Biophys. Acta Biomembr. 2017;1859 Pt B:1558–1572. doi: 10.1016/j.bbamem.2017.04.006. [DOI] [PubMed] [Google Scholar]
- 24.Kimura A.K., Kimura T. Phosphatidylserine biosynthesis pathways in lipid homeostasis: Toward resolution of the pending central issue for decades. FASEB J. 2021;35:e21177. doi: 10.1096/fj.202001802R. [DOI] [PubMed] [Google Scholar]
- 25.Futerman A.H., Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol. 2005;15:312–318. doi: 10.1016/j.tcb.2005.04.006. [DOI] [PubMed] [Google Scholar]
- 26.Funai K., Summers S.A., Rutter J. Reign in the membrane: How common lipids govern mitochondrial function. Curr. Opin. Cell Biol. 2020;63:162–173. doi: 10.1016/j.ceb.2020.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Vance J.E. Phospholipid synthesis and transport in mammalian cells. Traffic. 2015;16:1–18. doi: 10.1111/tra.12230. [DOI] [PubMed] [Google Scholar]
- 28.Aloulou A., Rahier R., Arhab Y., Noiriel A., Abousalham A. Phospholipases: An Overview. Methods Mol. Biol. 2018;1835:69–105. doi: 10.1007/978-1-4939-8672-9_3. [DOI] [PubMed] [Google Scholar]
- 29.Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957;226:497–509. doi: 10.1016/S0021-9258(18)64849-5. [DOI] [PubMed] [Google Scholar]
- 30.Lofgren L., Forsberg G.B., Stahlman M. The BUME method: A new rapid and simple chloroform-free method for total lipid extraction of animal tissue. Sci. Rep. 2016;6:27688. doi: 10.1038/srep27688. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Mirzaian M., Kramer G., Poorthuis B.J. Quantification of sulfatides and lysosulfatides in tissues and body fluids by liquid chromatography-tandem mass spectrometry. J. Lipid Res. 2015;56:936–943. doi: 10.1194/jlr.M057232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959;37:911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
- 33.Zhang T., Chen S., Syed I., Stahlman M., Kolar M.J., Homan E.A., Chu Q., Smith U., Boren J., Kahn B.B., et al. A LC-MS-based workflow for measurement of branched fatty acid esters of hydroxy fatty acids. Nat. Protoc. 2016;11:747–763. doi: 10.1038/nprot.2016.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Cajka T., Fiehn O. Comprehensive analysis of lipids in biological systems by liquid chromatography-mass spectrometry. Trends Anal. Chem. 2014;61:192–206. doi: 10.1016/j.trac.2014.04.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Hu T., Zhang J.L. Mass-spectrometry-based lipidomics. J. Sep. Sci. 2018;41:351–372. doi: 10.1002/jssc.201700709. [DOI] [PubMed] [Google Scholar]
- 36.Essaid D., Rosilio V., Daghildjian K., Solgadi A., Vergnaud J., Kasselouri A., Chaminade P. Artificial plasma membrane models based on lipidomic profiling. Biochim. Biophys. Acta. 2016;1858:2725–2736. doi: 10.1016/j.bbamem.2016.07.010. [DOI] [PubMed] [Google Scholar]
- 37.Schlotterbeck J., Chatterjee M., Gawaz M., Lammerhofer M. Comprehensive MS/MS profiling by UHPLC-ESI-QTOF-MS/MS using SWATH data-independent acquisition for the study of platelet lipidomes in coronary artery disease. Anal. Chim. Acta. 2019;1046:1–15. doi: 10.1016/j.aca.2018.08.060. [DOI] [PubMed] [Google Scholar]
- 38.Holcapek M., Liebisch G., Ekroos K. Lipidomic Analysis. Anal. Chem. 2018;90:4249–4257. doi: 10.1021/acs.analchem.7b05395. [DOI] [PubMed] [Google Scholar]
- 39.Lee H.C., Yokomizo T. Applications of mass spectrometry-based targeted and non-targeted lipidomics. Biochem. Biophys. Res. Commun. 2018;504:576–581. doi: 10.1016/j.bbrc.2018.03.081. [DOI] [PubMed] [Google Scholar]
- 40.Ekroos K., Ejsing C.S., Bahr U., Karas M., Simons K., Shevchenko A. Charting molecular composition of phosphatidylcholines by fatty acid scanning and ion trap MS3 fragmentation. J. Lipid Res. 2003;44:2181–2192. doi: 10.1194/jlr.D300020-JLR200. [DOI] [PubMed] [Google Scholar]
- 41.Ejsing C.S., Sampaio J.L., Surendranath V., Duchoslav E., Ekroos K., Klemm R.W., Simons K., Shevchenko A. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry. Proc. Natl. Acad. Sci. USA. 2009;106:2136–2141. doi: 10.1073/pnas.0811700106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Yang K., Han X. Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences. Trends Biochem. Sci. 2016;41:954–969. doi: 10.1016/j.tibs.2016.08.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Khoury S., El Banna N., Tfaili S., Chaminade P. A study of inter-species ion suppression in electrospray ionization-mass spectrometry of some phospholipid classes. Anal. Bioanal. Chem. 2016;408:1453–1465. doi: 10.1007/s00216-015-9245-6. [DOI] [PubMed] [Google Scholar]
- 44.Singer S.J., Nicolson G.L. The fluid mosaic model of the structure of cell membranes. Science. 1972;175:720–731. doi: 10.1126/science.175.4023.720. [DOI] [PubMed] [Google Scholar]
- 45.Nicolson G.L. The Fluid-Mosaic Model of Membrane Structure: Still relevant to understanding the structure, function and dynamics of biological membranes after more than 40 years. Biochim. Biophys. Acta. 2014;1838:1451–1466. doi: 10.1016/j.bbamem.2013.10.019. [DOI] [PubMed] [Google Scholar]
- 46.Doktorova M., Symons J.L., Levental I. Structural and functional consequences of reversible lipid asymmetry in living membranes. Nat. Chem. Biol. 2020;16:1321–1330. doi: 10.1038/s41589-020-00688-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Doktorova M. On the Long and Winding Road to a Perfect Membrane Model. Biophys. J. 2020;118:273–275. doi: 10.1016/j.bpj.2019.11.3386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Steck T.L., Lange Y. Transverse distribution of plasma membrane bilayer cholesterol: Picking sides. Traffic. 2018;19:750–760. doi: 10.1111/tra.12586. [DOI] [PubMed] [Google Scholar]
- 49.Vance J.E. Phospholipid synthesis in a membrane fraction associated with mitochondria. J. Biol. Chem. 1990;265:7248–7256. doi: 10.1016/S0021-9258(19)39106-9. [DOI] [PubMed] [Google Scholar]
- 50.Vance J.E. Newly made phosphatidylserine and phosphatidylethanolamine are preferentially translocated between rat liver mitochondria and endoplasmic reticulum. J. Biol. Chem. 1991;266:89–97. doi: 10.1016/S0021-9258(18)52406-6. [DOI] [PubMed] [Google Scholar]
- 51.Boncompagni S., Pozzer D., Viscomi C., Ferreiro A., Zito E. Physical and Functional Cross Talk Between Endo-Sarcoplasmic Reticulum and Mitochondria in Skeletal Muscle. Antioxid. Redox Signal. 2019;32:873–883. doi: 10.1089/ars.2019.7934. [DOI] [PubMed] [Google Scholar]
- 52.Giacomello M., Pellegrini L. The coming of age of the mitochondria-ER contact: A matter of thickness. Cell Death Differ. 2016;23:1417–1427. doi: 10.1038/cdd.2016.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Heden T.D., Neufer P.D., Funai K. Looking Beyond Structure: Membrane Phospholipids of Skeletal Muscle Mitochondria. Trends Endocrinol. Metab. 2016;27:553–562. doi: 10.1016/j.tem.2016.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Vance J.E. MAM (mitochondria-associated membranes) in mammalian cells: Lipids and beyond. Biochim. Biophys. Acta. 2014;1841:595–609. doi: 10.1016/j.bbalip.2013.11.014. [DOI] [PubMed] [Google Scholar]
- 55.Dorn G.W., 2nd, Maack C. SR and mitochondria: Calcium cross-talk between kissing cousins. J. Mol. Cell. Cardiol. 2013;55:42–49. doi: 10.1016/j.yjmcc.2012.07.015. [DOI] [PubMed] [Google Scholar]
- 56.Piquereau J., Novotova M., Fortin D., Garnier A., Ventura-Clapier R., Veksler V., Joubert F. Postnatal development of mouse heart: Formation of energetic microdomains. J. Physiol. 2010;588 Pt 13:2443–2454. doi: 10.1113/jphysiol.2010.189670. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Yang Y., Lee M., Fairn G.D. Phospholipid subcellular localization and dynamics. J. Biol. Chem. 2018;293:6230–6240. doi: 10.1074/jbc.R117.000582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Adhyapak P., Kapoor S. Membrane Dynamics in Health and Disease: Impact on Cellular Signalling. J. Membr. Biol. 2019;252:213–226. doi: 10.1007/s00232-019-00087-0. [DOI] [PubMed] [Google Scholar]
- 59.Giacomello E., Crea E., Torelli L., Bergamo A., Reggiani C., Sava G., Toniolo L. Age Dependent Modification of the Metabolic Profile of the Tibialis Anterior Muscle Fibers in C57BL/6J Mice. Int. J. Mol. Sci. 2020;21:3923. doi: 10.3390/ijms21113923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Nohara K., Kim E., Wirianto M., Mileykovskaya E., Dowhan W., Chen Z., Yoo S.H. Cardiolipin Synthesis in Skeletal Muscle Is Rhythmic and Modifiable by Age and Diet. Oxidative Med. Cell. Longev. 2020;2020:5304768. doi: 10.1155/2020/5304768. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Janikiewicz J., Szymanski J., Malinska D., Patalas-Krawczyk P., Michalska B., Duszynski J., Giorgi C., Bonora M., Dobrzyn A., Wieckowski M.R. Mitochondria-associated membranes in aging and senescence: Structure, function, and dynamics. Cell Death Dis. 2018;9:332. doi: 10.1038/s41419-017-0105-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Yaffe M.P. Dynamic mitochondria. Nat. Cell Biol. 1999;1:E149–E150. doi: 10.1038/14101. [DOI] [PubMed] [Google Scholar]
- 63.Bozdaganyan M.E., Lokhmatikov A.V., Voskoboynikova N., Cherepanov D.A., Steinhoff H.J., Shaitan K.V., Mulkidjanian A.Y. Proton leakage across lipid bilayers: Oxygen atoms of phospholipid ester linkers align water molecules into transmembrane water wires. Biochim. Biophys. Acta Bioenerg. 2019;1860:439–451. doi: 10.1016/j.bbabio.2019.03.001. [DOI] [PubMed] [Google Scholar]
- 64.Hishikawa D., Valentine W.J., Iizuka-Hishikawa Y., Shindou H., Shimizu T. Metabolism and functions of docosahexaenoic acid-containing membrane glycerophospholipids. FEBS Lett. 2017;591:2730–2744. doi: 10.1002/1873-3468.12825. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.van Meer G., de Kroon A.I. Lipid map of the mammalian cell. J. Cell Sci. 2011;124 Pt 1:5–8. doi: 10.1242/jcs.071233. [DOI] [PubMed] [Google Scholar]
- 66.Tyler A.I.I., Greenfield J.L., Seddon J.M., Brooks N.J., Purushothaman S. Coupling Phase Behavior of Fatty Acid Containing Membranes to Membrane Bio-Mechanics. Front. Cell Dev. Biol. 2019;7:187. doi: 10.3389/fcell.2019.00187. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.McNeil P.L., Steinhardt R.A. Plasma membrane disruption: Repair, prevention, adaptation. Annu. Rev. Cell Dev. Biol. 2003;19:697–731. doi: 10.1146/annurev.cellbio.19.111301.140101. [DOI] [PubMed] [Google Scholar]
- 68.Patel D., Witt S.N. Ethanolamine and Phosphatidylethanolamine: Partners in Health and Disease. Oxidative Med. Cell. Longev. 2017;2017:4829180. doi: 10.1155/2017/4829180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Lamari F., Mochel F., Sedel F., Saudubray J.M. Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: Toward a new category of inherited metabolic diseases. J. Inherit. Metab. Dis. 2013;36:411–425. doi: 10.1007/s10545-012-9509-7. [DOI] [PubMed] [Google Scholar]
- 70.Wortmann S.B., Espeel M., Almeida L., Reimer A., Bosboom D., Roels F., de Brouwer A.P., Wevers R.A. Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids. J. Inherit. Metab. Dis. 2015;38:99–110. doi: 10.1007/s10545-014-9759-7. [DOI] [PubMed] [Google Scholar]
- 71.Barth P.G., Valianpour F., Bowen V.M., Lam J., Duran M., Vaz F.M., Wanders R.J. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): An update. Am. J. Med. Genet. A. 2004;126A:349–354. doi: 10.1002/ajmg.a.20660. [DOI] [PubMed] [Google Scholar]
- 72.Damschroder D., Reynolds C., Wessells R. Drosophila tafazzin mutants have impaired exercise capacity. Physiol. Rep. 2018;6:e13604. doi: 10.14814/phy2.13604. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Zegallai H.M., Hatch G.M. Barth syndrome: Cardiolipin, cellular pathophysiology, management, and novel therapeutic targets. Mol. Cell. Biochem. 2021;476:1605–1629. doi: 10.1007/s11010-020-04021-0. [DOI] [PubMed] [Google Scholar]
- 74.Mayr J.A., Haack T.B., Graf E., Zimmermann F.A., Wieland T., Haberberger B., Superti-Furga A., Kirschner J., Steinmann B., Baumgartner M.R., et al. Lack of the mitochondrial protein acylglycerol kinase causes Sengers syndrome. Am. J. Hum. Genet. 2012;90:314–320. doi: 10.1016/j.ajhg.2011.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Sengers R.C., Trijbels J.M., Willems J.L., Daniels O., Stadhouders A.M. Congenital cataract and mitochondrial myopathy of skeletal and heart muscle associated with lactic acidosis after exercise. J. Pediatrics. 1975;86:873–880. doi: 10.1016/S0022-3476(75)80217-4. [DOI] [PubMed] [Google Scholar]
- 76.Jiang H., Yu Z., Ding N., Yang M., Zhang L., Fan X., Zhou Y., Zou Q., Hou J., Zheng J., et al. The role of AGK in thrombocytopoiesis and possible therapeutic strategies. Blood. 2020;136:119–129. doi: 10.1182/blood.2019003851. [DOI] [PubMed] [Google Scholar]
- 77.Allali S., Dorboz I., Samaan S., Slama A., Rambaud C., Boespflug-Tanguy O., Sarret C. Mutation in the AGK gene in two siblings with unusual Sengers syndrome. Metab. Brain Dis. 2017;32:2149–2154. doi: 10.1007/s11011-017-0101-6. [DOI] [PubMed] [Google Scholar]
- 78.Zeharia A., Shaag A., Houtkooper R.H., Hindi T., de Lonlay P., Erez G., Hubert L., Saada A., de Keyzer Y., Eshel G., et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am. J. Hum. Genet. 2008;83:489–494. doi: 10.1016/j.ajhg.2008.09.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Donkor J., Sariahmetoglu M., Dewald J., Brindley D.N., Reue K. Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J. Biol. Chem. 2007;282:3450–3457. doi: 10.1074/jbc.M610745200. [DOI] [PubMed] [Google Scholar]
- 80.Csaki L.S., Reue K. Lipins: Multifunctional lipid metabolism proteins. Annu. Rev. Nutr. 2010;30:257–272. doi: 10.1146/annurev.nutr.012809.104729. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Rashid T., Nemazanyy I., Paolini C., Tatsuta T., Crespin P., de Villeneuve D., Brodesser S., Benit P., Rustin P., Baraibar M.A., et al. Lipin1 deficiency causes sarcoplasmic reticulum stress and chaperone-responsive myopathy. EMBO J. 2019;38:e99576. doi: 10.15252/embj.201899576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Reilich P., Horvath R., Krause S., Schramm N., Turnbull D.M., Trenell M., Hollingsworth K.G., Gorman G.S., Hans V.H., Reimann J. The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene. J. Neurol. 2011;258:1987–1997. doi: 10.1007/s00415-011-6055-4. [DOI] [PubMed] [Google Scholar]
- 83.Wu J.W., Wang S.P., Alvarez F., Casavant S., Gauthier N., Abed L., Soni K.G., Yang G., Mitchell G.A. Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. Hepatology. 2011;54:122–132. doi: 10.1002/hep.24338. [DOI] [PubMed] [Google Scholar]
- 84.Rao M., Guo G., Li M., Chen S., Chen K., Chen X., Song J., Hu S. The homozygous variant c.245G > A/p.G82D in PNPLA2 is associated with arrhythmogenic cardiomyopathy phenotypic manifestations. Clin. Genet. 2019;96:532–540. doi: 10.1111/cge.13642. [DOI] [PubMed] [Google Scholar]
- 85.Li M., Hirano K.I., Ikeda Y., Higashi M., Hashimoto C., Zhang B., Kozawa J., Sugimura K., Miyauchi H., Suzuki A., et al. Triglyceride deposit cardiomyovasculopathy: A rare cardiovascular disorder. Orphanet J Rare Dis. 2019;14:134. doi: 10.1186/s13023-019-1087-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Sher R.B., Aoyama C., Huebsch K.A., Ji S., Kerner J., Yang Y., Frankel W.N., Hoppel C.L., Wood P.A., Vance D.E., et al. A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis. J. Biol. Chem. 2006;281:4938–4948. doi: 10.1074/jbc.M512578200. [DOI] [PubMed] [Google Scholar]
- 87.Mitsuhashi S., Hatakeyama H., Karahashi M., Koumura T., Nonaka I., Hayashi Y.K., Noguchi S., Sher R.B., Nakagawa Y., Manfredi G., et al. Muscle choline kinase beta defect causes mitochondrial dysfunction and increased mitophagy. Hum. Mol. Genet. 2011;20:3841–3851. doi: 10.1093/hmg/ddr305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Mitsuhashi S., Ohkuma A., Talim B., Karahashi M., Koumura T., Aoyama C., Kurihara M., Quinlivan R., Sewry C., Mitsuhashi H., et al. A congenital muscular dystrophy with mitochondrial structural abnormalities caused by defective de novo phosphatidylcholine biosynthesis. Am. J. Hum. Genet. 2011;88:845–851. doi: 10.1016/j.ajhg.2011.05.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Sayed-Zahid A.A., Sher R.B., Sukoff Rizzo S.J., Anderson L.C., Patenaude K.E., Cox G.A. Functional rescue in a mouse model of congenital muscular dystrophy with megaconial myopathy. Hum. Mol. Genet. 2019;28:2635–2647. doi: 10.1093/hmg/ddz068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Blondelle J., Ohno Y., Gache V., Guyot S., Storck S., Blanchard-Gutton N., Barthelemy I., Walmsley G., Rahier A., Gadin S., et al. HACD1, a regulator of membrane composition and fluidity, promotes myoblast fusion and skeletal muscle growth. J. Mol. Cell Biol. 2015;7:429–440. doi: 10.1093/jmcb/mjv049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Prola A., Blondelle J., Vandestienne A., Piquereau J., Denis R.G.P., Guyot S., Chauvin H., Mourier A., Maurer M., Henry C., et al. Cardiolipin content controls mitochondrial coupling and energetic efficiency in muscle. Sci. Adv. 2021;7:eabd6322. doi: 10.1126/sciadv.abd6322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Abbasi-Moheb L., Westenberger A., Alotaibi M., Alghamdi M.A., Hertecant J.L., Ariamand A., Beetz C., Rolfs A., Bertoli-Avella A.M., Bauer P. Biallelic loss-of-function HACD1 variants are a bona fide cause of congenital myopathy. Clin. Genet. 2021;99:513–518. doi: 10.1111/cge.13905. [DOI] [PubMed] [Google Scholar]
- 93.Gregersen N. The acyl-CoA dehydrogenation deficiencies. Recent advances in the enzymic characterization and understanding of the metabolic and pathophysiological disturbances in patients with acyl-CoA dehydrogenation deficiencies. Scand. J. Clin. Lab. Investig. Suppl. 1985;174:1–60. [PubMed] [Google Scholar]
- 94.Strauss A.W., Powell C.K., Hale D.E., Anderson M.M., Ahuja A., Brackett J.C., Sims H.F. Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc. Natl. Acad. Sci. USA. 1995;92:10496–10500. doi: 10.1073/pnas.92.23.10496. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Tucci S., Flogel U., Spiekerkoetter U. Sexual dimorphism of lipid metabolism in very long-chain acyl-CoA dehydrogenase deficient (VLCAD-/-) mice in response to medium-chain triglycerides (MCT) Biochim. Biophys. Acta. 2015;1852:1442–1450. doi: 10.1016/j.bbadis.2015.04.009. [DOI] [PubMed] [Google Scholar]
- 96.Tucci S., Alatibi K.I., Wehbe Z. Altered Metabolic Flexibility in Inherited Metabolic Diseases of Mitochondrial Fatty Acid Metabolism. Int. J. Mol. Sci. 2021;22:3799. doi: 10.3390/ijms22073799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Vengalil S., Preethish-Kumar V., Polavarapu K., Christopher R., Gayathri N., Natarajan A., Manjunath M., Nashi S., Prasad C., Nalini A. Fatty acid oxidation defects presenting as primary myopathy and prominent dropped head syndrome. Neuromuscul. Disord. 2017;27:986–996. doi: 10.1016/j.nmd.2017.08.004. [DOI] [PubMed] [Google Scholar]
- 98.Stanley C.A. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. Adv. Pediatrics. 1987;34:59–88. [PubMed] [Google Scholar]
- 99.Tolwani R.J., Hamm D.A., Tian L., Sharer J.D., Vockley J., Rinaldo P., Matern D., Schoeb T.R., Wood P.A. Medium-chain acyl-CoA dehydrogenase deficiency in gene-targeted mice. PLoS Genet. 2005;1:e23. doi: 10.1371/journal.pgen.0010023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Lim S.C., Tajika M., Shimura M., Carey K.T., Stroud D.A., Murayama K., Ohtake A., McKenzie M. Loss of the Mitochondrial Fatty Acid beta-Oxidation Protein Medium-Chain Acyl-Coenzyme A Dehydrogenase Disrupts Oxidative Phosphorylation Protein Complex Stability and Function. Sci. Rep. 2018;8:153. doi: 10.1038/s41598-017-18530-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Scheuerman O., Wanders R.J., Waterham H.R., Dubnov-Raz G., Garty B.Z. Mitochondrial trifunctional protein deficiency with recurrent rhabdomyolysis. Pediatric Neurol. 2009;40:465–467. doi: 10.1016/j.pediatrneurol.2008.12.017. [DOI] [PubMed] [Google Scholar]
- 102.Ibdah J.A., Paul H., Zhao Y., Binford S., Salleng K., Cline M., Matern D., Bennett M.J., Rinaldo P., Strauss A.W. Lack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death. J. Clin. Investig. 2001;107:1403–1409. doi: 10.1172/JCI12590. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Fraser H., Geppert J., Johnson R., Johnson S., Connock M., Clarke A., Taylor-Phillips S., Stinton C. Evaluation of earlier versus later dietary management in long-chain 3-hydroxyacyl-CoA dehydrogenase or mitochondrial trifunctional protein deficiency: A systematic review. Orphanet J. Rare Dis. 2019;14:258. doi: 10.1186/s13023-019-1226-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.Dorfman M.L., Hershko C., Eisenberg S., Sagher F. Ichthyosiform dermatosis with systemic lipidosis. Arch. Dermatol. 1974;110:261–266. doi: 10.1001/archderm.1974.01630080059017. [DOI] [PubMed] [Google Scholar]
- 105.Lefevre C., Jobard F., Caux F., Bouadjar B., Karaduman A., Heilig R., Lakhdar H., Wollenberg A., Verret J.L., Weissenbach J., et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am. J. Hum. Genet. 2001;69:1002–1012. doi: 10.1086/324121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Oberer M., Boeszoermenyi A., Nagy H.M., Zechner R. Recent insights into the structure and function of comparative gene identification-58. Curr. Opin. Lipidol. 2011;22:149–158. doi: 10.1097/MOL.0b013e328346230e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Jebessa Z.H., Shanmukha K.D., Dewenter M., Lehmann L.H., Xu C., Schreiter F., Siede D., Gong X.M., Worst B.C., Federico G., et al. The lipid droplet-associated protein ABHD5 protects the heart through proteolysis of HDAC4. Nat. Metab. 2019;1:1157–1167. doi: 10.1038/s42255-019-0138-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Radner F.P., Streith I.E., Schoiswohl G., Schweiger M., Kumari M., Eichmann T.O., Rechberger G., Koefeler H.C., Eder S., Schauer S., et al. Growth retardation, impaired triacylglycerol catabolism, hepatic steatosis, and lethal skin barrier defect in mice lacking comparative gene identification-58 (CGI-58) J. Biol. Chem. 2010;285:7300–7311. doi: 10.1074/jbc.M109.081877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.North K.N., Hoppel C.L., De Girolami U., Kozakewich H.P., Korson M.S. Lethal neonatal deficiency of carnitine palmitoyltransferase II associated with dysgenesis of the brain and kidneys. J. Pediatrics. 1995;127:414–420. doi: 10.1016/S0022-3476(95)70073-0. [DOI] [PubMed] [Google Scholar]
- 110.Corti S., Bordoni A., Ronchi D., Musumeci O., Aguennouz M., Toscano A., Lamperti C., Bresolin N., Comi G.P. Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency. J. Neurol. Sci. 2008;266:97–103. doi: 10.1016/j.jns.2007.09.015. [DOI] [PubMed] [Google Scholar]
- 111.Pereyra A.S., Hasek L.Y., Harris K.L., Berman A.G., Damen F.W., Goergen C.J., Ellis J.M. Loss of cardiac carnitine palmitoyltransferase 2 results in rapamycin-resistant, acetylation-independent hypertrophy. J. Biol. Chem. 2017;292:18443–18456. doi: 10.1074/jbc.M117.800839. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Land J.M., Mistry S., Squier M., Hope P., Ghadiminejad I., Orford M., Saggerson D. Neonatal carnitine palmitoyltransferase-2 deficiency: A case presenting with myopathy. Neuromuscul. Disord. 1995;5:129–137. doi: 10.1016/0960-8966(94)00037-A. [DOI] [PubMed] [Google Scholar]
- 113.Begam M., Roche R., Hass J.J., Basel C.A., Blackmer J.M., Konja J.T., Samojedny A.L., Collier A.F., Galen S.S., Roche J.A. The effects of concentric and eccentric training in murine models of dysferlin-associated muscular dystrophy. Muscle Nerve. 2020;62:393–403. doi: 10.1002/mus.26906. [DOI] [PubMed] [Google Scholar]
- 114.Kobayashi K., Izawa T., Kuwamura M., Yamate J. Dysferlin and animal models for dysferlinopathy. J. Toxicol. Pathol. 2012;25:135–147. doi: 10.1293/tox.25.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Roche J.A., Ru L.W., Bloch R.J. Distinct effects of contraction-induced injury in vivo on four different murine models of dysferlinopathy. J. Biomed. Biotechnol. 2012;2012:134031. doi: 10.1155/2012/134031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Tan S.M.L., Ong C.C., Tan K.B., Chin H.L., Paliwal P.R., Ng K.W.P., Lin W. Subclinical Cardiomyopathy in Miyoshi Myopathy Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Imaging. Int. Heart J. 2021;62:186–192. doi: 10.1536/ihj.20-354. [DOI] [PubMed] [Google Scholar]
- 117.Benabdellah F., Yu H., Brunelle A., Laprevote O., De La Porte S. MALDI reveals membrane lipid profile reversion in MDX mice. Neurobiol. Dis. 2009;36:252–258. doi: 10.1016/j.nbd.2009.07.013. [DOI] [PubMed] [Google Scholar]
- 118.Blake D.J., Weir A., Newey S.E., Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 2002;82:291–329. doi: 10.1152/physrev.00028.2001. [DOI] [PubMed] [Google Scholar]
- 119.Dabaj I., Ferey J., Marguet F., Gilard V., Basset C., Bahri Y., Brehin A.C., Vanhulle C., Leturcq F., Marret S., et al. Muscle metabolic remodelling patterns in Duchenne muscular dystrophy revealed by ultra-high-resolution mass spectrometry imaging. Sci. Rep. 2021;11:1906. doi: 10.1038/s41598-021-81090-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.McGreevy J.W., Hakim C.H., McIntosh M.A., Duan D. Animal models of Duchenne muscular dystrophy: From basic mechanisms to gene therapy. Dis. Models Mech. 2015;8:195–213. doi: 10.1242/dmm.018424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Senoo N., Miyoshi N., Kobayashi E., Morita A., Tanihata J., Takeda S., Miura S. Glycerophospholipid profile alterations are associated with murine muscle-wasting phenotype. Muscle Nerve. 2020;62:413–418. doi: 10.1002/mus.26993. [DOI] [PubMed] [Google Scholar]
- 122.Touboul D., Piednoel H., Voisin V., De La Porte S., Brunelle A., Halgand F., Laprevote O. Changes of phospholipid composition within the dystrophic muscle by matrix-assisted laser desorption/ionization mass spectrometry and mass spectrometry imaging. Eur. J. Mass Spectrom. 2004;10:657–664. doi: 10.1255/ejms.671. [DOI] [PubMed] [Google Scholar]
- 123.Tuazon M.A., Henderson G.C. Fatty acid profile of skeletal muscle phospholipid is altered in mdx mice and is predictive of disease markers. Metabolism. 2012;61:801–811. doi: 10.1016/j.metabol.2011.10.019. [DOI] [PubMed] [Google Scholar]
- 124.Woodman S.E., Park D.S., Cohen A.W., Cheung M.W., Chandra M., Shirani J., Tang B., Jelicks L.A., Kitsis R.N., Christ G.J. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J. Biol. Chem. 2002;277:38988–38997. doi: 10.1074/jbc.M205511200. [DOI] [PubMed] [Google Scholar]
- 125.Shah D.S., Nisr R.B., Stretton C., Krasteva-Christ G., Hundal H.S. Caveolin-3 deficiency associated with the dystrophy P104L mutation impairs skeletal muscle mitochondrial form and function. J. Cachexia Sarcopenia Muscle. 2020;11:838–858. doi: 10.1002/jcsm.12541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Chen J., Zeng W., Han C., Wu J., Zhang H., Tong X. Mutation in the caveolin-3 gene causes asymmetrical distal myopathy. Neuropathology. 2016;36:485–489. doi: 10.1111/neup.12297. [DOI] [PubMed] [Google Scholar]
- 127.Pradhan B.S., Proszynski T.J. A Role for Caveolin-3 in the Pathogenesis of Muscular Dystrophies. Int. J. Mol. Sci. 2020;21:8736. doi: 10.3390/ijms21228736. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128.Garlid A.O., Schaffer C.T., Kim J., Bhatt H., Guevara-Gonzalez V., Ping P. TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome. Gene. 2020;726:144148. doi: 10.1016/j.gene.2019.144148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Schlame M., Kelley R.I., Feigenbaum A., Towbin J.A., Heerdt P.M., Schieble T., Wanders R.J., DiMauro S., Blanck T.J. Phospholipid abnormalities in children with Barth syndrome. J. Am. Coll. Cardiol. 2003;42:1994–1999. doi: 10.1016/j.jacc.2003.06.015. [DOI] [PubMed] [Google Scholar]
- 130.Fajardo V.A., Mikhaeil J.S., Leveille C.F., Saint C., LeBlanc P.J. Cardiolipin content, linoleic acid composition, and tafazzin expression in response to skeletal muscle overload and unload stimuli. Sci. Rep. 2017;7:2060. doi: 10.1038/s41598-017-02089-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Ikon N., Ryan R.O. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy. Lipids. 2017;52:99–108. doi: 10.1007/s11745-016-4229-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.McKenzie M., Lazarou M., Thorburn D.R., Ryan M.T. Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients. J. Mol. Biol. 2006;361:462–469. doi: 10.1016/j.jmb.2006.06.057. [DOI] [PubMed] [Google Scholar]
- 133.Wasmus C., Dudek J. Metabolic Alterations Caused by Defective Cardiolipin Remodeling in Inherited Cardiomyopathies. Life. 2020;10:277. doi: 10.3390/life10110277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Bektas M., Payne S.G., Liu H., Goparaju S., Milstien S., Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J. Cell Biol. 2005;169:801–811. doi: 10.1083/jcb.200407123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Vukotic M., Nolte H., Konig T., Saita S., Ananjew M., Kruger M., Tatsuta T., Langer T. Acylglycerol Kinase Mutated in Sengers Syndrome Is a Subunit of the TIM22 Protein Translocase in Mitochondria. Mol. Cell. 2017;67:471–483.e7. doi: 10.1016/j.molcel.2017.06.013. [DOI] [PubMed] [Google Scholar]
- 136.Kang Y., Stroud D.A., Baker M.J., De Souza D.P., Frazier A.E., Liem M., Tull D., Mathivanan S., McConville M.J., Thorburn D.R. Sengers Syndrome-Associated Mitochondrial Acylglycerol Kinase Is a Subunit of the Human TIM22 Protein Import Complex. Mol. Cell. 2017;67:457–470.e5. doi: 10.1016/j.molcel.2017.06.014. [DOI] [PubMed] [Google Scholar]
- 137.Mitsuhashi S., Nishino I. Phospholipid synthetic defect and mitophagy in muscle disease. Autophagy. 2011;7:1559–1561. doi: 10.4161/auto.7.12.17925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Marchet S., Invernizzi F., Blasevich F., Bruno V., Dusi S., Venco P., Fiorillo C., Baranello G., Pallotti F., Lamantea E., et al. Alteration of mitochondrial membrane inner potential in three Italian patients with megaconial congenital muscular dystrophy carrying new mutations in CHKB gene. Mitochondrion. 2019;47:24–29. doi: 10.1016/j.mito.2019.04.002. [DOI] [PubMed] [Google Scholar]
- 139.Muhammad E., Reish O., Ohno Y., Scheetz T., Deluca A., Searby C., Regev M., Benyamini L., Fellig Y., Kihara A., et al. Congenital myopathy is caused by mutation of HACD1. Hum. Mol. Genet. 2013;22:5229–5236. doi: 10.1093/hmg/ddt380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 140.Paran C.W., Zou K., Ferrara P.J., Song H., Turk J., Funai K. Lipogenesis mitigates dysregulated sarcoplasmic reticulum calcium uptake in muscular dystrophy. Biochim. Et Biophys. Acta. 2015;1851:1530–1538. doi: 10.1016/j.bbalip.2015.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 141.Grounds M.D., Terrill J.R., Radley-Crabb H.G., Robertson T., Papadimitriou J., Spuler S., Shavlakadze T. Lipid accumulation in dysferlin-deficient muscles. Am. J. Pathol. 2014;184:1668–1676. doi: 10.1016/j.ajpath.2014.02.005. [DOI] [PubMed] [Google Scholar]
- 142.Haynes V.R., Keenan S.N., Bayliss J., Lloyd E.M., Meikle P.J., Grounds M.D., Watt M.J. Dysferlin deficiency alters lipid metabolism and remodels the skeletal muscle lipidome in mice. J. Lipid Res. 2019;60:1350–1364. doi: 10.1194/jlr.M090845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Bohnert K.R., McMillan J.D., Kumar A. Emerging roles of ER stress and unfolded protein response pathways in skeletal muscle health and disease. J. Cell. Physiol. 2018;233:67–78. doi: 10.1002/jcp.25852. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 144.Pitts M.W., Hoffmann P.R. Endoplasmic reticulum-resident selenoproteins as regulators of calcium signaling and homeostasis. Cell Calcium. 2018;70:76–86. doi: 10.1016/j.ceca.2017.05.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.